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OBJECTIVES The aim of this study was to determine whether discontinuation of low-molecular-weight
heparin (LMWH) treatment results in a clustering of cardiac ischemic events as previously
observed after cessation of unfractionated heparin (UFH) in acute coronary syndrome (ACS)
patients.
BACKGROUND Clinical trials in patients with ACS have shown early recurrent ischemic events after discontin-
uation of UFH treatment. We analyzed whether LMWH cessation also results in early ischemic
recurrence events and if continuation of a fixed-dose LMWH prevents this complication.
METHODS The combined incidence of death, myocardial infarction, or urgent revascularization in the
first seven days after discontinuation of UFH (n  3,012), short-term enoxaparin 1 mg/kg
subcutaneously twice a day (n  2,011), and short-term enoxaparin followed by prolonged
enoxaparin 60 mg subcutaneously twice a day (n  1,075) was analyzed from the combined
Thrombolysis In Myocardial Infarction (TIMI) 11B/Efficacy and Safety of Subcutaneous
Enoxaparin in Non–Q-Wave Coronary Events (ESSENCE) database in a per patient
analysis.
RESULTS The cessation of both UFH and short-term enoxaparin resulted in a similar clustering of
recurrent ischemic events on the first day, with an incidence of the primary end point of 2.8%
in both groups. Of all recurrent events in the first week after cessation, 40% occurred in the
first 24 h. The continuation of a fixed-dose enoxaparin treatment prevented this early excess,
with a first day incidence of 0.4% (p 0.0001). The TIMI risk score characteristics predicted
the incidence of early rebound ischemic events.
CONCLUSIONS There is significant clustering of recurrent ischemic events within 24 h after cessation of both
short-term UFH and enoxaparin treatment, and patients should be carefully monitored
during that period. This early rebound may be prevented by continuation of a fixed dose of
enoxaparin. (J Am Coll Cardiol 2003;42:2083–9) © 2003 by the American College of
Cardiology Foundation
Several studies in patients with acute coronary syndromes
(ACS) have described the recurrence of ischemic events
shortly after cessation of unfractionated heparin (UFH)
treatment (1–4). In the Global Use of Strategies To Open
occluded arteries in acute coronary syndromes (GUSTO I)
study, 33% of all recurrent myocardial infarctions (MIs)
occurring in the first week after UFH was discontinued
occurred within 10 h (2). In an Efficacy and Safety of
Subcutaneous Enoxaparin in Non–Q-Wave Coronary
Events (ESSENCE) substudy, a higher incidence of isch-
emic ST-segment episodes was observed in the 48 h after
UFH and low-molecular-weight heparin (LMWH) treat-
ment than during the first 48 h of treatment (3), although
the data suggest that the incidence was lower after LMWH
treatment than after UFH treatment. A more recent pub-
lication also observed this very early clustering of rebound
ischemia after discontinuation of UFH, with a peak inci-
dence as early as 4 h after discontinuation (4).
To date, one study (5) reported an increased event rate when
therapeutic LMWH treatment was discontinued, reducing its
benefit compared with placebo in the acute phase.
We investigated whether cessation of UFH or LMWH
resulted in a clinical rebound and whether these compounds
differ in this respect. We used data derived from the large
ESSENCE (6) and Thrombolysis In Myocardial Infarction
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(TIMI) 11B (7) trials and calculated in a per patient analysis
the incidence of ischemic events after discontinuation of
either UFH or enoxaparin. The prolonged fixed-dose
LMWH treatment arm of the TIMI 11B trial allowed us to
study the effect of this regimen on rebound phenomena.
METHODS
Protocol and patient population of the TIMI 11B and
ESSENCE studies. The study protocols have been de-
scribed in previous publications (6,7). In short, patients with
unstable angina or non–Q-wave infarction, presenting
within 24 h after onset of symptoms, were eligible for
inclusion. A total of 7,081 patients were randomized, in a
double dummy design, to intravenous UFH (n  3,521) or
subcutaneous enoxaparin (n 3,560). In both studies, UFH
treatment was continued for at least three days with a
maximum of eight days. In both studies, enoxaparin was
administered at a dose of 1 mg/kg twice a day and was
continued until day 8 or hospital discharge. The TIMI 11B
protocol required continuation of enoxaparin treatment
with a fixed dose of 60 mg twice a day until day 43. All
patients received aspirin 100 to 325 mg/day.
Principal results of the TIMI 11B and ESSENCE
studies. The end points of the separate TIMI 11B and
ESSENCE studies, as well as the combined end points of
these studies have been published previously (6–8). Treat-
ment with enoxaparin resulted in a 20% reduction of the
composite end point death or non-fatal MI, with an
absolute reduction from 5.3% to 4.1% by day 8 (odds ratio
[OR]  0.77; confidence interval [CI] 0.62 to 0.95) and
from 8.6% to 7.1% by day 43 (OR 0.82; CI 0.69 to 0.97).
The treatment benefit of enoxaparin over UFH occurred
rapidly after the start of treatment with a significant end
point reduction as early as day 2 after randomization.
Enoxaparin and UFH showed a similar rate of major
hemorrhage (approximately 1.2%) although a higher rate of
minor hemorrhage was observed with enoxaparin treatment
(10% vs. 4.3%).
Patient selection for the current analysis. All patients
from the TIMI 11B and ESSENCE trials were eligible for
the present study if they had received in-hospital study
treatment (n  7,081).
Not included were patients in whom study drug treat-
ment times were not available (n  41), or in whom
in-hospital study drug was administered for more than 14
days (n  5), on oral anticoagulant treatment after study
drug treatment (n  29), or who died during study
in-hospital drug treatment (n  16). We excluded patients
who underwent revascularization during study drug treat-
ment because of confounding effects of procedural compli-
cations and the use of additional antithrombotic medication
(n  239), and patients who underwent revascularization
within 48 h after cessation of study drug without recurrent
angina between cessation and revascularization because of
the probability that the indication for the intervention was
established before study drug discontinuation or irrespective
of the clinical course (n  653). As a result, 6,098 patients
were included in the present analysis (Table 1).
We considered the following patient groups: patients
who had received short-term UFH (UFH group, n 
3,012), patients who had received short-term in-hospital
enoxaparin treatment only (ShortEnox group, n  2,011),
and patients who had received short-term in-hospital enox-
aparin followed by long-term out-of-hospital continuation
of enoxaparin treatment (LongEnox group, n  1,075).
The time of discontinuation of study drug for patients
Abbreviations and Acronyms
ACS  acute coronary syndromes
CI  confidence interval
ESSENCE  Efficacy and Safety of Subcutaneous
Enoxaparin in Non–Q-Wave Coronary
Events
LMWH  low-molecular-weight heparin
LongEnox  long-term out-hospital continuation of
enoxaparin treatment
MI  myocardial infarction
OR  odds ratio
ShortEnox  short-term in-hospital enoxaparin
treatment
TIMI  Thrombolysis In Myocardial Infarction
UFH  unfractionated heparin
Table 1. Patient Selection for Current Analysis
Randomized
Treatment Group
Total
N  7,081
UFH
N  3,521
ShortEnox
N  2,381
LongEnox
N  1,179
Exclusion
Treatment 14 days n  1 n  2 n  2 N  5
Treatment duration missing n  25 n  15 n  1 N  41
Revascularization during Rx n  102 n  93 n  44 N  239
Revascularization 48 h after Rx
without angina
n  367 n  231 n  55 N  653
Oral anticoagulants n  13 n  14 n  2 N  29
Death during Rx n  1 n  15 n  0 N  16
Total exclusion n  509 n  370 n  104 N  983
Total inclusion n  3,012 n  2,011 n  1,075 N  6,098
LongEnox  long-term enoxaparin; Rx  treatment; ShortEnox  short-term enoxaparin; UFH  unfractionated heparin.
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treated with UFH was defined as the time at which the
infusion was stopped. For patients treated with enoxaparin,
the time of discontinuation of treatment was defined as 12 h
after the last full in-hospital enoxaparin dose, after which
plasma drug levels fall below the therapeutic range.
End point definitions and data analysis. The primary end
point for the current analysis was a composite of mortality,
(recurrent) MI, or recurrent ischemia leading to urgent
revascularization occurring after discontinuation. Secondary
end points were: mortality; mortality or (recurrent) MI; and
mortality, (recurrent) MI, or severe recurrent ischemia with
or without urgent revascularization. End point definitions
have been presented in the original reports (6,7). A (recur-
rent) MI was defined as rise of creatine kinase-MB fraction
above normal or 50% increase, or creatine kinase rise 2
times upper limit and increased by 25% over previous
value, or new Q waves.
The incidence of the primary and secondary end points
was calculated for the first 7 days after treatment discontin-
uation by calculating, for each 24-h period, the percentage
of patients who developed a first end point among those
patients who had not previously developed that end point.
We compared the incidence of the primary end point on the
first day after discontinuation with the incidence on the
subsequent days. Furthermore, to observe if reactivation of
an ischemic event occurred in these stabilized patients (n 
6,098) (Table 1), the incidence of the primary end point of
the day before study drug continuation was calculated. By
definition, patients who either died or underwent an urgent
revascularization during treatment were excluded, thus the
incidence of MI was calculated. It is not possible to compare
the incidence of clinical events after discontinuation with
the incidence during study drug administration, because in
the design of this analysis as well as previous similar analyses
(4,9), the end points death and revascularization could not
occur before discontinuation.
TIMI risk factors and recurrent ischemic events. To
identify whether cardiac risk factors, identified at random-
ization, were associated with early rebound events after
treatment cessation, the TIMI risk score was related to the
incidence of early rebound (10).
Statistics. Baseline characteristics between the three
groups were compared with an analysis of variance for
continuous baseline variables, a chi-square test used for
non-continuous variables, and a Kruskal-Wallis analysis for
non-parametric variables. Differences between the treat-
ment groups in incidences of the primary and secondary end
points were analyzed using the chi-square test. For the
relationship between the number of risk factors and the
incidence of rebound events, a Wilcoxon test was
performed.
RESULTS
Patient characteristics. The patient characteristics of the
UFH group, the ShortEnox group, and the LongEnox
group are presented in Table 2. Compared with the UFH
and ShortEnox groups, patients in the LongEnox group
consisted of more males (4%), had a lower prevalence of a
family history of coronary artery disease (5%), hyperten-
sion (4%), hypercholesterolemia (5%), previous MI
(8%), a higher prevalence of aspirin use (8%), and had a
higher number of TIMI risk factors. The in-hospital treat-
ment duration was longer in the LongEnox group.
Clinical events after study drug discontinuation. The
cumulative incidence of the primary end point during the
first seven days after treatment cessation is shown in Figure
1. The UFH and ShortEnox groups showed a significantly
Table 2. Characteristics of Study Patients Treated With UFH and Enoxaparin for At Least
48 h but 14 Days
Characteristics
Treatment Group
p Value
UFH
(n  3,012)
ShortEnox
(n  2,011)
LongEnox
(n  1,075)
Age (yrs) 64.4 63.9 63.7 0.2
Male (%) 63.9 64.3 68.1 0.04
Family history of CAD (%) 38.2 39.7 34.7 0.02
Current smoker (%) 25.5 25.4 26.7 0.7
History of hypertension (%) 51.3 52.8 47.8 0.03
History of hypercholesterolemia (%) 36.2 41.3 34.5 0.001
History of diabetes (%) 20.9 20.8 22.5 0.5
Previous myocardial infarction (%) 39.6 41.3 32.7 0.001
Previous aspirin use (%) 75.3 69.6 82.1 0.001
Previous beta-blocker use (%) 38.4 37.5 34.3 0.06
Median acute, in-hospital treatment
duration (days  25th/75th percentile)
3.0 (2.2/3.8) 3.4 (2.5/5.1) 5.8 (3.9/7.2) 0.0001
Mean TIMI risk score 3.1 2.9 3.4 0.0001
TIMI risk factors distribution (%)
0–2 33 40 23
3–4 55 51 59 0.001
5–7 12 9 18
CAD  coronary artery disease; TIMI  Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
}
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higher incidence of ischemic events compared with the
LongEnox group (UFH vs. LongEnox, p  0.0001; Short-
Enox vs. LongEnox, p  0.0003 at day 7). The greatest
difference in event rates was observed on the first day after
cessation of treatment.
For the UFH and ShortEnox groups, the incidence of the
primary end point on the first day after study drug discon-
tinuation was 2.9% and 2.8%, respectively, and the hazard
on day 1 was substantially greater than that on subsequent
days (i.e., 2 to 7 days) and before discontinuation (i.e., day
1) (Fig. 2, Table 3). In the UFH and ShortEnox groups,
39% and 46%, respectively of all primary end point events in
the first week occurred on the first day. The incidence on
day 1 and day 2 after cessation in the UFH group was 2.9%
and 1.1%, respectively (p  0.0001), and 2.8% and 0.4% in
the ShortEnox group, respectively (p  0.0001). This early
rebound in the UFH and ShortEnox groups was also observed
for the separate end points death and MI (Table 3).
An excess of risk during the first 24 h was not observed in
the LongEnox group, with constant event rates from day
1 to day 7, with an incidence of the primary outcome on
days 1 and 2 after cessation of 0.4% and 0.7%, respectively
(p  0.4).
Reactivation in the patients treated in the UFH and
ShortEnox groups was apparent, with event rates on the day
before discontinuation of 0.6% in the UFH group and 0.8%
in the ShortEnox group, respectively (Table 3). The
LongEnox group showed no reactivation with similar event
rates on the day before discontinuation and day 1 after
cessation (0.2% vs. 0.4%, respectively).
The mean time to the occurrence of clinical events was
7.3 and 9.0 h after the presumed loss of therapeutic UFH
and short-term enoxaparin plasma drug levels, respectively
(i.e., 7.3 h after discontinuation of UFH infusion, 21 h after
last enoxaparin injection). On the first day as well as in the
first week, the incidences of the primary end point and of
the individual clinical end points were significantly lower in
the LongEnox group than in the other two groups (Table
3). Additionally, the combined end points death/MI and
death/MI/severe recurrent ischemia showed similar high
incidences on day 1 after cessation compared with the
following days for both the UFH and ShortEnox groups
and not for the LongEnox group (data not shown). The
cessation of long-term enoxaparin after six weeks showed no
rebound of ischemic events.
TIMI risk factors and recurrent ischemic events. Figure
3 relates the number of TIMI risk factors with the incidence
of early rebound (i.e., events within 24 h after the cessation
of treatment). In both the UFH and ShortEnox groups, a
clear relationship between TIMI risk score and event rate
was observed, with an increase in the incidence of early
Figure 1. Cumulative incidence for the occurrence of death, myocardial infarction, or urgent revascularization by treatment group during the first seven days
after treatment discontinuation. LongEnox  long-term out-hospital continuation of enoxaparin treatment; ShortEnox  short-term in-hospital
enoxaparin treatment; UFH  unfractionated heparin.
Figure 2. Hazard of death, myocardial infarction, or urgent revasculariza-
tion per day during the day before (1) and days (1 to 7) after
discontinuation of UFH or short-term enoxaparin. Note: by definition, day
1 (i.e., 24 h before treatment discontinuation) does not include patients
who died or underwent an urgent revascularization. Abbreviations as in
Figure 1.
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rebound proportional to the number of risk factors. Patients
with TIMI risk scores of 0 to 4 had a rebound incidence of
2.2%, whereas patients with scores of 5 to 7 had an
incidence of 4.5%. The LongEnox group revealed no
rebound events in the 0/1 and 2 risk-factors groups, and low
incidences in the 3, 4, and 5 risk-factors groups of 0.3%,
0.4%, and 1.2%, respectively. No events occurred in patients
with 6/7 risk factors; however, there was a very low number
of patients in this group (n  33). At any level of risk, the
LongEnox group had a lower incidence of events, with a
statistically significant difference in the groups with 2, 3, and
4 risk factors (p  0.007, p  0.009, and p  0.048,
respectively, UFH group  ShortEnox vs. LongEnox).
DISCUSSION
The discontinuation of both short-term UFH and short-
term enoxaparin treatment resulted in a clustering of isch-
emic events on the first day after cessation of treatment. Of
all recurrent end points occurring in the week after discon-
tinuation of these treatments, approximately 40% occurred
within 24 h after cessation. Early rebound was observed for
death, MI, urgent revascularization, and severe recurrent
ischemia, indicating that the composite end point was not
driven by a single event.
Moreover, this reactivation of ischemic event occurs in
patients who are considered stable, and who may be trans-
ferred home or to other facilities on that first day after
discontinuation of anticoagulation.
The continuation of a fixed reduced dose of enoxaparin
treatment was associated with less early rebound, and with
a significantly lower total incidence of recurrent ischemia
during one week of follow-up. It was associated with a lower
incidence in patients at all levels of risk but was most
effective in patients with a TIMI risk score of 3 to 7, where
it reduced the primary end point by approximately 80%
(Fig. 3). The cessation of long-term enoxaparin treatment
did not lead to an increase of events and showed similar
incidence rates on days 1 and 2 after cessation.
The TIMI risk scores were different among the three
treatments groups (Table 2). However, as the mean risk
score in the LongEnox group was higher than in the other
two groups, these differences do not explain the lower
incidence of rebound in the LongEnox group.
In our analysis, we found no difference in the incidence of
rebound events between UFH and short-term enoxaparin
(both 2.8%). In an ESSENCE substudy (3), a higher
incidence of ST-segment shifts was observed after UFH
treatment compared with that after enoxaparin treatment.
However, this was a small study, and (silent) ST-segment
shifts may only partially reflect recurrent thrombotic events.
Other factors such as tachycardia, anemia, or coronary
spasm may contribute to these episodes.
Patients continuing to chronic-phase LMWH treatment
Table 3. Incidence of Ischemic Events on the Day Before Treatment Discontinuation (Day 1),
and the First Day and the First Week After UFH or Short-Term Enoxaparin
Treatment Cessation
Treatment Group
p Value*
Risk Ratio
[95% CI]*
UFH
(n  3,012)
ShortEnox
(n  2,011)
LongEnox
(n  1,075)
On treatment day 1
Primary 0.6% (19) 0.8% (6) 0.2% (2) 0.2 0.37 [0.09–1.49]
Off treatment day 1
Primary 2.9% (86) 2.8% (57) 0.4% (4) 0.000005 0.13 [0.06–0.30]
Death 0.9% (26) 0.8% (17) 0.1% (1) 0.007 0.16 [0.02–0.55]
MI 0.6% (17) 0.4% (8) 0.0% (0) 0.02 n.e.
Off treatment day 1–7
Primary 7.3% (221) 6.2% (124) 3.2% (34) 0.000005 0.46 [0.33–0.64]
Death 2.1% (63) 1.9% (39) 0.5% (5) 0.0004 0.23 [0.10–0.52]
MI 2.1% (63) 1.2% (25) 1.1% (12) 0.1 0.64 [0.35–1.15]
Primary end point was a composite of death, MI, or urgent revascularization. Data are presented as percentages, with absolute
event rates in parentheses. *p value and risk ratio of UFH plus ShortEnox versus LongEnox.
CI  confidence interval; LongEnox  long-term enoxaparin group; MI  myocardial infarction; n.e.  not estimable;
ShortEnox  short-term enoxaparin group; UFH  unfractionated heparin group.
Figure 3. The Thrombolysis In Myocardial Infarction (TIMI) risk factor
distribution in patients with early rebound, that is, occurrence of a primary
end point event within 24 h after discontinuation of treatment. Abbrevi-
ations as in Figure 1.
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were different from the short treatment groups with respect
to several baseline characteristics (Table 2). However, the
TIMI risk score, which has been shown to predict events in
this particular population, was equal among the treatment
groups, indicating that the overall risk is not lower in
patients continuing into the chronic phase (Table 1).
A possible cause for this early rebound phenomenon is
remaining coronary thrombus, posing a threat for recurrent
occlusion. This hypothesis is supported by a study by van
Belle et al. (11), visualizing angioscopically thrombus ma-
terial in the coronary artery up to four weeks after hospital
admission for MI.
Platelet activation may be important for the occurrence of
early rebound. Clot-bound thrombin is a potent trigger for
platelet activation and thrombus growth. Aspirin reduces
the risk of rebound (1); however, early rebound does occur
in acetylsalicylic acid-treated patients (2,4). More aggressive
platelet inhibition with glycoprotein IIb/IIIa inhibitors
further lowers the risk of rebound events in ACS patients
(9).
Other mechanisms that could lead to a transient hyper-
coagulable state include depletion of natural anticoagulants
such as tissue-factor pathway inhibitor and antithrombin
(12–17). This is supported by the highly increased thrombin
generation and activation markers observed 3 to 24 h after
both UFH and LMWH treatment cessation, with pro-
thrombin fragments 1  2 levels exceeding pretreatment
prothrombin fragments 1  2 levels (18). This observation
suggests a drug-related phenomenon of thrombin genera-
tion as opposed to a return to the natural course after
treatment cessation. However, the fact that no early recur-
rences were observed after discontinuation of long-term
enoxaparin suggests that this drug-related phenomenon is
dependent on the activity of the underlying thrombotic
process.
Whether these results imply that treatment with UFH or
LMWH should be continued beyond the short-term regi-
men is unclear. Several ACS studies, including the TIMI
11B study, examined the possible benefit of prolonged
LMWH treatment (7,19,20). Results were consistent and
showed no benefit. However, a selection of ACS patients do
benefit from prolonged anticoagulation treatment as shown
in a recent study (21). High-risk patients, based on elevated
troponin T levels and ST-segment deviation on admission,
showed a clear and significant reduction in death or MI
during the 90-day treatment period compared with short-
term LMWH. Unfortunately, this treatment effect was
gradually lost after LMWH was discontinued, resulting in
equal rates of death or MI at one-year follow-up. Our study
indicates that most benefit from prolonged treatment may
be obtained in patients with three or more risk factors (Fig.
3). However, these patients represent approximately 65% of
the total group.
The lack of efficacy in long-term LMWH treatment may
also be related to the patient’s compliance during home
treatment (22). In the Fragmin during Instability in Coro-
nary Artery Disease (FRISC) II study, anti-factor Xa
measurements during follow-up showed a steady decline,
dropping from 0.6 U/ml at the start to 0.4 U/ml at three
months, with 29% of the patients showing levels smaller
than 0.2 U/ml. Thus, a substantial proportion of patients
had subtherapeutic levels during home treatment.
Several strategies may potentially reduce the incidence of
recurrent ischemic events. First, gradual weaning of the dose
of the anticoagulant has been shown to decrease the extent
of rebound coagulation (14). Second, clinicians may decide
not to discharge or transfer a patient until at least 24 h after
drug discontinuation, particularly in high-risk subgroups.
Third, as rebound thrombin generation peaks between 6
and 12 h after discontinuation (18), it may be advisable to
stop UFH infusion early in the morning in order to manage
possible recurrences during daytime. Similarly, by schedul-
ing the last LMWH dose in the evening, a fall in drug levels
below the therapeutic range will occur in the morning.
However, these recommendations have not been tested
prospectively.
Study limitations. This study has several limitations. This
was a post hoc analysis using prospectively acquired data,
which focused on a selection of the total included patient
population from the TIMI 11B and ESSENCE studies. A
total of 983 (14%) patients were not included in the rebound
analysis; 14% of the UFH group patients, 16% of the
ShortEnox group patients, and 9% of the LongEnox group
were excluded (Table 1). A significant proportion of exclu-
sions consisted of patients in whom a revascularization was
performed within 48 h after treatment cessation without
recurrent anginal symptoms. The decision to revascularize
these patients was apparently made on other clinical
grounds during heparin treatment, and these patients were
switched to open-label UFH before the intervention. Po-
tentially, the benefits of revascularization versus a conserva-
tive approach, as demonstrated in recent randomized trials
(23–25) could be explained by a reduction in rebound
thrombotic events. However, because of selection bias and
differences in pharmacologic treatments, this cannot be
established from our data. The incidence of death or MI
during the first four days after randomization was similar
between the included and excluded patients.
The different stopping time for UFH and enoxaparin was
based on the markedly longer therapeutic anticoagulant
effect of enoxaparin as compared with UFH. After the last
administration of enoxaparin, anti-Xa plasma levels remain
in the therapeutic range between 12 and 15 h, whereas
cessation of intravenous UFH is rapidly cleared after the
infusion is stopped, resulting in nearly undetectable anti-Xa
levels at 3 h (18).
Conclusions. Recurrent ischemic events were observed in a
significant proportion of patients early after discontinuation
of UFH and LMWH treatment. The majority of these
events occurred within 24 h, and clinical predictors may
identify patients at high risk. Continuing (fixed-dose) ad-
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ministration of LMWH may prevent these early recur-
rences, especially in high-risk groups.
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